<DOC>
	<DOCNO>NCT01132482</DOCNO>
	<brief_summary>Dehydrated airway surface result sodium hyperabsorption lack chloride secretion critical pathology lead morbidity mortality Cystic Fibrosis ( CF ) lung disease . Previously publish work CF cell line demonstrate increase cGMP restore inhibition ENaC , sodium hyperabsorption may reverse follow administration phosphodiesterase inhibitor ( PDEi , ) sildenafil . Additionally show CF cell line animal model , phosphodiesterase inhibitors/analogues enhance chloride secretion and/or correct surface localization ΔF508 CFTR . The goal project translate result work laboratory clinical trial patient CF use FDA-approved therapy . The Specific Aims project : 1 ) Evaluate effect systemically administer phosphodiesterase inhibitor ion transport CF measurement Na+ Cl- conductance NPD Na+ Cl- concentration sweat utilizing pilocarpine iontophoresis 2 ) To establish appropriate dose sildenafil CF perform dose-escalation study patient carefully monitor side effect , plasma sildenafil level obtain outcome measure compare base dose sildenafil administer . The result study conjunction ongoing study examine role sildenafil anti-inflammatory CF aid establish safety , pharmacokinetics mechanism action sildenafil treatment CF lung disease .</brief_summary>
	<brief_title>Effects Sildenafil CFTR-dependent Ion Transport Activity</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>1 . Confirmed diagnosis CF base follow criterion : Positive sweat chloride ≥60mEq/liter ( pilocarpine iontophoresis ) genotype two F508del CFTR mutation , accompany one clinical feature consistent CF phenotype 2 . Male female subject ≥ 18 year age 3 . FEV1 ≥ 50 % predict ( Hankinson ) 4 . Clinically stable without evidence acute upper low respiratory tract infection current pulmonary exacerbation within 14 day prior screen visit 5 . Ability reproducibly perform spirometry ( accord ATS criterion ) 6 . Ability understand sign write informed consent assent comply requirement study 7 . Willing able perform nasal potential difference test 8 . No change use nasal medication within 2 week screen visit 9 . If Orkambi , stable Orkambi dose least 4 week day 1 . 1 . History hypersensitivity sildenafil 2 . Use investigational agent within 4week period prior Visit 1 ( Day 0 ) 3 . Breastfeeding , pregnant , verbal expression unwillingness practice acceptable birth control method ( abstinence , hormonal barrier method , partner sterilization intrauterine device ) participation study 4 . History significant hepatic ( SGOT SGPT &gt; 3 time upper limit normal screening , document biliary cirrhosis , portal hypertension ) , cardiovascular ( history aortic stenosis , coronary artery disease , pulmonary hypertension right ventricular systolic pressure &gt; 55 mmHg lifethreatening arrhythmia ) , neurological ( history stroke ) , hematologic ( history bleed diathesis ) , ophthalmologic ( history retinal impairment nonarteritic ischemic optic neuritis ) renal impairment ( creatinine &gt; 1.8 mg/dL . ) 5 . Inability swallow pill 6 . Previous lung transplantation 7 . Use concomitant nitrate , αblocker , Ca channel blocker 8 . Use concomitant medication know potent inhibitor CYP3A4 ( e.g . ketoconazole , itraconazole , ritonavir , clarithromycin , erythromycin , rifampin , verapamil ) 9 . Presence condition abnormality opinion investigator would compromise safety subject quality data 10 . Weight le 40 kg 11 . History sputum throat swab culture yield Burkholderia cepacia within 2 year screen 12 . History nasal disease nasal surgery would , opinion investigator , impede accurate measurement NPD 13 . Use anticoagulant medication ( e.g . heparin , coumadin ) 14 . Resting room air oxygen saturation &lt; 93 % 15 . Use nighttime oxygen 15 ) History migraine headache 16 ) Baseline BP &lt; 90/50 mm Hg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cystic fibrosis</keyword>
	<keyword>CFTR</keyword>
	<keyword>Phosphodiesterase inhibitor</keyword>
	<keyword>Nasal potential difference</keyword>
	<keyword>Sweat test</keyword>
</DOC>